2022 news preview: Expect a row over controversial Alzheimer's drug

In 2021, the US approved the first drug designed to treat the cause of Alzheimer's, but the European Union rejected it. Whether the drug can actually treat the chief symptoms of the disease will be a point of contention in 2022

Related Keywords

United Kingdom ,Kayana Szymczak ,Henry Magendantz ,Clare Wilson ,European Medicines Agency ,Drug Administration ,Susan Kohlhaas At Alzheimer Research United Kingdom ,Regulatory Agency ,Butler Hospital ,New York Times ,Susan Kohlhaas ,Research United ,New Scientist ,Alzheimer 039s Disease ,Aducanumab ,Fda ,Medicine ,